Education and Training
Low-Dose Naltrexone for the Treatment of Complex Regional Pain Syndrome
The investigators are testing treatment with low-dose naltrexone (LDN) for symptom relief of complex regional pain syndrome (CRPS). Study participants will be randomly assigned to receive either LDN or placebo for a period of several weeks. During this period participants will be asked to attend either in-person or virtual study visits and complete questionnaires.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: LDN
- drug: Placebo
Eligibility
Inclusion Criteria:
- Upper and/or lower extremity CRPS
- On stable treatment for 1 month
- CRPS for at least 1 year
- Meet the Budapest criteria for CRPS at time of the study.
Exclusion Criteria:
- Any known allergy to naltrexone or naloxone
- Use of prescription opioid analgesics or illegal opioid use
- Current or planned pregnancy.
Ages Eligible for Study
18 Years - 70 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Birute Gedrimaite
650-497-0485
I'm interested